0001225208-19-000433.txt : 20190103
0001225208-19-000433.hdr.sgml : 20190103
20190103165514
ACCESSION NUMBER: 0001225208-19-000433
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20190101
FILED AS OF DATE: 20190103
DATE AS OF CHANGE: 20190103
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ballinger Kevin J.
CENTRAL INDEX KEY: 0001566080
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11083
FILM NUMBER: 19506484
MAIL ADDRESS:
STREET 1: C/O BOSTON SCIENTIFIC CORPORATION
STREET 2: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752-1234
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP
CENTRAL INDEX KEY: 0000885725
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 042695240
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752-1234
BUSINESS PHONE: 508-683-4000
MAIL ADDRESS:
STREET 1: 300 BOSTON SCIENTIFIC WAY
CITY: MARLBOROUGH
STATE: MA
ZIP: 01752-1234
4
1
doc4.xml
X0306
4
2019-01-01
0000885725
BOSTON SCIENTIFIC CORP
BSX
0001566080
Ballinger Kevin J.
300 BOSTON SCIENTIFIC WAY
MARLBOROUGH
MA
01752-1234
1
EVP & Pres, Interven Cardio
Common Stock
2018-11-06
5
G
0
2385.0000
0.0000
D
69623.0000
D
Common Stock
2019-01-01
4
M
0
21502.0000
0.0000
A
91125.0000
D
Common Stock
2019-01-01
4
F
0
6762.0000
35.3400
D
84363.0000
D
Performance Share Units
0.0000
2019-01-01
4
M
0
21502.0000
0.0000
D
2018-12-31
2018-12-31
Common Stock
21502.0000
0.0000
D
Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available.
On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2016 adjusted free cash flow measured against its 2016 financial plan over the one-year performance period ending December 31, 2016 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 28, 2017, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined vested in whole upon the completion of the individual service period that ends on December 31, 2018.
Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock.
ballingerpoa.txt
/s/ Vance R. Brown, Attorney-in-fact
2019-01-03
EX-24
2
ballingerpoa.txt
POWER OF ATTORNEY
Know all by these present that the undersigned hereby constitutes and
appoints each of Desiree Ralls-Morrison, Vance R. Brown, Scott Hodgdon, Ashley
E.
McGrane and Mai-KhoiNguyen-Thanh signing singly, the undersigned's true and
lawful attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the undersigned's
capacity as an executive officer and/or director of Boston Scientific
Corporation
(the "Company"), Forms 3, 4 and 5, and amendments thereto, in accordance with
Section 16(a) of the Securities Exchange Act of 1934 and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to complete and execute any such Form 3, 4
or 5
and file such form with the United States Securities and Exchange
Commission and any stock exchange or similar authority;
(3) execute for and on behalf of the undersigned, in the undersigned's capacity
as an executive officer and/or director of the Company, Forms 144 in accordance
with Rule 144 of the Securities Exchange Act of 1933, as amended and the rules
and regulations thereunder; and
(4) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in
the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might
or could do if personally present, with full power of substitution or
revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted.
The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in
such capacity at the request of the undersigned, are not assuming, nor is the
Company assuming, any of the undersigned's responsibilities to comply with
Section 16 of the Securities Exchange Act of 1934 or Rule 144 of the Securities
Act of 1933, as amended.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 and Forms 144 with
respect to the undersigned's holdings of and transactions in securities issued
by the Company, unless earlier revoked by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney
to be executed as of this 3rd day of January, 2019.
/s/ Kevin Ballinger
________________
Kevin Ballinger